title: Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression?
authors.forename: Jerome
authors.initials: J
authors.lastname: Rossert
authors.forename: William M
authors.initials: WM
authors.lastname: McClellan
authors.forename: Simon D
authors.initials: SD
authors.lastname: Roger
authors.forename: Dierik L
authors.initials: DL
authors.lastname: Verbeelen
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D017209:Apoptosis; D004921:Erythropoietin / Q000627:therapeutic use*; D005355:Fibrosis; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007684:Kidney Tubules / Q000473:pathology; D008954:Models, Biological; D018384:Oxidative Stress; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin